ESRRA and colonic neoplasm: At last, we combined trametinib with simvastatin, a drug commonly used in the clinic, which has a new reported function of suppressing the transcriptional activity of ERRα [28], and the results showed that this combination synergised to inhibit proliferation and colony formation in vitro as well as the in vivo tumourigenic capacity of colon cancer cells.